|
Roldán V, Marín F. Pro: "Antidote for new anticoagulants"--specific target of inhibition requires a specific target for neutralisation. Thromb Haemost. 2012 Oct;108(4):621-2. Epub 2012 Aug 23. Review. PubMed PMID: 22918294.
AÑO: 2012; IF: 6.094
|
22918294
|
Marín F, Roldán V, Lip GY. Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable? Expert Opin Pharmacother. 2012 Jun;13(8):1087-90. doi: 10.1517/14656566.2012.688954. Epub 2012 May 9. PubMed PMID: 22568622.
AÑO: 2012; IF: 2.86
|
|
López-Cuenca AA, Tello-Montoliu A, Roldán V, Pérez-Berbel P, Valdés M, Marín F. Prognostic value of mean platelet volume in patients with non-ST-elevation acute coronary syndrome. Angiology. 2012 May;63(4):241-4. doi: 10.1177/0003319711413892. Epub 2011 Jul 6. PubMed PMID: 21733947.
AÑO: 2012; IF: 1.647
|
|
Ruiz-Nodar JM, Marín F, Roldán V, Valencia J, Manzano-Fernández S, Caballero L, Hurtado JA, Sogorb F, Valdés M, Lip GY. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Circ Cardiovasc Interv. 2012 Aug 1;5(4):459-66. doi: 10.1161/CIRCINTERVENTIONS.112.968792. Epub 2012 Jul 10. PubMed PMID: 22787018.
AÑO: 2012; IF: 6.543
|
|
Gallego P, Roldán V, Torregrosa JM, Gálvez J, Valdés M, Vicente V, Marín F, Lip GY. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2012 Apr;5(2):312-8. doi: 10.1161/CIRCEP.111.967000. Epub 2012 Feb 7. PubMed PMID: 22319005.
AÑO: 2012; IF: 1.241
|